BioCentury | Jul 10, 2020
Deals

Data Bytes: Kymera-Sanofi deal is latest sign targeted degradation is growing up

Kymera and Sanofi’s deal brings the targeted protein degradation space its largest disclosed upfront and most advanced partnered asset to date. The companies announced Thursday that Sanofi (Euronext:SAN; NASDAQ:SNY) will pay Kymera Therapeutics Inc. $150...
BioCentury | Jun 30, 2020
Product Development

Low-stakes 2018 deal with Regeneron leads to bump for Kiniksa on pericarditis readout

Pivotal data for rilonacept in recurrent pericarditis put Kiniksa on track to bring its first program to market and gain rights from Regeneron to additional indications. Kiniksa Pharmaceuticals Ltd. (NASDAQ:KNSA) shares rose $2.97 (13%) to...
BioCentury | Jun 27, 2020
Product Development

A mechanistic view of four compounds that disrupt interleukin pathways to treat severe COVID-19

Master protocols for COVID-19 clinical trials are testing half a dozen molecules that aim to prevent respiratory distress in patients with severe disease by targeting the host immune system -- four of these compounds intervene...
BioCentury | Mar 19, 2020
Product Development

Roivant pivots towards ARDS in COVID-19; plus Italian studies of repurposed anti-inflammatories, vaccine updates and more

Wednesday saw a full slate of clinical updates across the globe for vaccine and therapeutic candidates to address COVID-19, while HHS launched a new public-private partnership to ramp up emergency drug packaging capabilities. Roivant Sciences...
BioCentury | Mar 12, 2020
Product Development

Targeted degradation gets another bump with Kymera’s $102M raise

It’s a big year for targeted protein degraders, and Kymera is adding to the momentum with a $102 million series C round that should bring its first three programs into the clinic. Biotechnology Value Fund...
BioCentury | Jan 30, 2020
Distillery Therapeutics

IL1RL1 in Treg cells as a lung cancer target

DISEASE CATEGORY: Cancer INDICATION: Lung cancer Inhibiting IL1RL1, which signals in response to IL-33 binding, in Treg cells could treat lung cancer. In single-cell RNA sequencing analyses of CD4 + T cells from the lymph...
BC Extra | Nov 8, 2019
Clinical News

AnaptysBio left with slimmer pipeline after eczema candidate fails Phase IIb

AnaptysBio lost over $700 million in market cap Friday after reporting that IL-33 inhibitor etokimab, which it had hoped would compete with blockbuster inflammatory disease drug Dupixent, missed the primary endpoint in a trial to...
BC Extra | Oct 23, 2019
Clinical News

Arvinas clears key hurdle, showing PROTACs orally bioavailable in clinic

Putting to rest concerns regarding oral bioavailability, Arvinas showed that its first two proteolysis-targeting chimeras achieved serum levels predicted to be efficacious. Wednesday’s presentation of Phase I data of ARV-110 for metastatic castration-resistant prostate cancer...
BC Innovations | Sep 25, 2019
Tools & Techniques

Locus co-founders open door to new CRISPR systems

As most gene editing companies remain laser-focused on the well-studied CRISPR-Cas9 system marred in IP disputes, a new study from Locus co-founders shows that an entirely different type of CRISPR system can tune gene expression...
BC Innovations | Aug 23, 2019
Targets & Mechanisms

New targets in osteoarthritis are about more than just pain

New biological insights and increased recognition from FDA are transforming osteoarthritis from a testing ground for new pain therapies into its own high-priority indication. At least two mechanisms with disease-modifying potential for osteoarthritis (OA) have...
Items per page:
1 - 10 of 194